Compare HCC & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | TMDX |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.2B |
| IPO Year | 2017 | 2019 |
| Metric | HCC | TMDX |
|---|---|---|
| Price | $101.00 | $141.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $76.40 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 750.1K | 660.2K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | 0.67 | ★ 2.54 |
| Revenue | ★ $1,224,320,000.00 | $566,354,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | $47.01 | $20.49 |
| P/E Ratio | $149.58 | ★ $56.53 |
| Revenue Growth | N/A | ★ 41.20 |
| 52 Week Low | $38.00 | $55.00 |
| 52 Week High | $105.35 | $156.00 |
| Indicator | HCC | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 79.63 | 63.09 |
| Support Level | $86.85 | $134.00 |
| Resistance Level | $105.35 | $151.85 |
| Average True Range (ATR) | 3.36 | 6.57 |
| MACD | 0.77 | 1.73 |
| Stochastic Oscillator | 77.05 | 68.91 |
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.